{"gene":"PITRM1","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2016,"finding":"PITRM1 is a mitochondrial matrix enzyme responsible for degrading mitochondrial targeting sequences (MTS) cleaved from imported precursor proteins and for digesting the mitochondrial fraction of amyloid-beta (Aβ). A homozygous missense mutation (p.Arg183Gln) reduces its proteolytic activity, resulting in Aβ accumulation in patient fibroblasts, skeletal muscle, and a yeast model. Heterozygous Pitrm1+/- mice develop progressive ataxia with brain Aβ-positive amyloid deposits, providing direct mechanistic evidence that PITRM1 loss impairs Aβ clearance leading to amyloidotic neurodegeneration.","method":"In vitro peptidase activity assay, patient fibroblast and skeletal muscle analysis, yeast complementation model, heterozygous mouse model with neuropathology","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods across in vitro, cellular, yeast, and mouse models; replicated across subsequent independent studies","pmids":["26697887"],"is_preprint":false},{"year":2018,"finding":"A novel PITRM1 missense mutation (p.T931M) reduces PITRM1 protein levels by ~95% and specifically impairs cleavage of peptides ≥40 amino acids, demonstrating that the length of the substrate peptide is a determinant of PITRM1 enzymatic activity, with longer peptides being preferentially affected by this variant.","method":"Whole exome/genome sequencing, quantitative peptide cleavage activity assays in patient cells and yeast model","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct peptide cleavage activity assay plus yeast modeling, single lab","pmids":["29764912"],"is_preprint":false},{"year":2020,"finding":"PITRM1 deficiency in human iPSC-derived cortical neurons strongly induces the mitochondrial unfolded protein response (UPRmt) and enhances mitochondrial clearance (mitophagy). PITRM1-knockout cerebral organoids spontaneously develop AD-like pathology including amyloid precursor protein and Aβ accumulation, tau pathology, protein aggregates, and neuronal cell death, establishing that impaired mitochondrial presequence processing triggers proteotoxic stress and UPRmt as an early protective response.","method":"PITRM1-knockout human iPSC-derived cortical neurons and cerebral organoids, single-cell RNA sequencing, immunohistochemistry for Aβ/tau/aggregates","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout in human iPSC-derived 3D organoid model with multiple orthogonal readouts (UPRmt, mitophagy, Aβ, tau, cell death, scRNA-seq)","pmids":["32632204"],"is_preprint":false},{"year":2021,"finding":"Increasing neuronal PITRM1 expression/activity in aged AD transgenic mice (up to 19–24 months) re-established mitochondrial respiration, suppressed reactive oxygen species, improved synaptic function, and reduced synapse loss. Loss of PITRM1 proteolytic activity (catalytic mutant) abolished these rescue effects and resulted in Aβ accumulation, demonstrating that PITRM1 proteolytic activity is specifically required for mitochondrial Aβ clearance and protection of mitochondrial and synaptic function.","method":"Transgenic mouse model overexpressing PITRM1 or proteolytic-dead PITRM1 in cortical neurons; mitochondrial respiration assay, ROS measurement, synaptic function assessment, Aβ quantification","journal":"Aging cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain-of-function and catalytic mutant (loss-of-function) in vivo with multiple orthogonal functional readouts in aged AD mouse model","pmids":["33951271"],"is_preprint":false},{"year":2021,"finding":"An in-frame 6-bp deletion in canine PITRM1 (loss of two N-terminal residues) causes severe mitochondrial respiratory chain deficiency in brain tissue, Aβ accumulation, and lethal epilepsy. Yeast modeling of the mutation confirmed impaired growth and reduced respiration capacity, establishing that the N-terminal domain of PITRM1 is required for proper protein function and mitochondrial respiratory integrity.","method":"Homozygosity mapping, genome sequencing, mitochondrial respiratory chain enzyme activity assay in brain tissue, yeast complementation model","journal":"Human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct respiratory chain assay in affected tissue plus yeast functional model, single lab","pmids":["33835239"],"is_preprint":false},{"year":2023,"finding":"PITRM1 dysfunction causes accumulation of mitochondrial targeting sequences (MTS), which dissipates mitochondrial membrane potential and triggers feedback inhibition of the mitochondrial processing peptidase (MPP), impairing maturation of Frataxin. Pharmacological activation of PPARG by pioglitazone upregulates both IDE and PITRM1 protein levels, restoring presequence processing, Frataxin maturation, and mitochondrial function in patient fibroblasts.","method":"MTS accumulation assay, mitochondrial membrane potential measurement, MPP activity assay, Frataxin maturation western blot, pharmacological treatment with pioglitazone in patient vs. control fibroblasts","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal biochemical assays in patient fibroblasts, single lab","pmids":["37576821"],"is_preprint":false},{"year":2009,"finding":"Mouse Pitrm1 expression is upregulated in response to loss of the Gli3 transcription factor and is expressed in Pax3-positive myoblast progenitors, dermomyotome, and developing muscles. Pitrm1 expression is regulated downstream of hedgehog signaling in the developing limb, placing it in the Shh/Gli3 pathway during embryonic development.","method":"In situ hybridization in Gli3, Shh null, and Ptch1 conditional mutant mouse limbs; co-expression with Pax3 lineage marker","journal":"Developmental dynamics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — expression/localization data in mutant mice without functional rescue or direct epistasis experiment","pmids":["19877269"],"is_preprint":false}],"current_model":"PITRM1 is a mitochondrial matrix zinc metallopeptidase that degrades mitochondrial targeting sequences (MTS) released after precursor protein import and clears the mitochondrial fraction of amyloid-beta (Aβ); loss of its proteolytic activity causes MTS accumulation, mitochondrial membrane potential dissipation, feedback inhibition of MPP (impairing Frataxin maturation), induction of the mitochondrial unfolded protein response, and progressive Aβ accumulation leading to neurodegeneration, while gain of PITRM1 activity restores mitochondrial respiration and synaptic function in AD mouse models."},"narrative":{"mechanistic_narrative":"PITRM1 is a mitochondrial matrix zinc metallopeptidase central to mitochondrial protein quality control, degrading the mitochondrial targeting sequences (presequences) released from imported precursor proteins and clearing the mitochondrial pool of amyloid-beta (Aβ) [PMID:26697887]. Its catalytic activity is required for these functions: a catalytically dead enzyme fails to clear Aβ and abolishes rescue of mitochondrial respiration and synaptic integrity in aged AD mouse models, whereas restoring PITRM1 activity re-establishes respiration, suppresses reactive oxygen species, and reduces synapse loss [PMID:33951271]. Substrate handling is length-dependent, with longer peptides (≥40 residues) preferentially affected by hypomorphic variants [PMID:29764912]. When PITRM1 is impaired, undegraded presequences accumulate and dissipate the mitochondrial membrane potential, which feeds back to inhibit the mitochondrial processing peptidase (MPP) and blocks Frataxin maturation [PMID:37576821]. Loss of activity also triggers the mitochondrial unfolded protein response and enhanced mitophagy as protective responses, while in human iPSC-derived cortical neurons and cerebral organoids PITRM1 deficiency drives Aβ and tau accumulation, protein aggregation, and neuronal death [PMID:32632204]. Human and canine loss-of-function mutations cause progressive neurodegeneration, ataxia, amyloid deposition, respiratory chain deficiency, and lethal epilepsy, establishing PITRM1 loss as a direct cause of amyloidotic neurodegenerative disease [PMID:26697887, PMID:33835239]. Pharmacological upregulation of PITRM1 by PPARG activation (pioglitazone) restores presequence processing and Frataxin maturation in patient fibroblasts [PMID:37576821].","teleology":[{"year":2016,"claim":"Established PITRM1 as a mitochondrial matrix peptidase whose loss impairs degradation of presequences and Aβ, causally linking it to amyloidotic neurodegeneration.","evidence":"In vitro peptidase assays, patient fibroblast/muscle analysis, yeast complementation, and a heterozygous mouse model with brain amyloid neuropathology","pmids":["26697887"],"confidence":"High","gaps":["Did not resolve substrate length preference or the structural basis of catalysis","Mechanism connecting presequence accumulation to downstream mitochondrial dysfunction not yet defined"]},{"year":2018,"claim":"Showed that substrate peptide length is a determinant of PITRM1 activity, with a hypomorphic variant selectively impairing cleavage of peptides ≥40 residues.","evidence":"Exome/genome sequencing plus quantitative peptide cleavage assays in patient cells and yeast","pmids":["29764912"],"confidence":"Medium","gaps":["Single lab; structural explanation for length selectivity not provided","Relationship between reduced protein level and intrinsic catalytic defect not separated"]},{"year":2020,"claim":"Defined the cellular consequences of PITRM1 loss in human neurons—UPRmt and mitophagy induction as early protective responses, with organoids developing full AD-like pathology.","evidence":"PITRM1-knockout iPSC-derived cortical neurons and cerebral organoids with scRNA-seq and Aβ/tau/aggregate immunohistochemistry","pmids":["32632204"],"confidence":"High","gaps":["Causal chain from presequence/Aβ accumulation to tau pathology not mechanistically dissected","Whether UPRmt induction is sufficient to delay degeneration untested"]},{"year":2021,"claim":"Demonstrated that PITRM1 proteolytic activity specifically protects mitochondrial respiration and synaptic function, since gain of activity rescues AD mice and a catalytic mutant abolishes rescue.","evidence":"Transgenic overexpression of wild-type vs. proteolytic-dead PITRM1 in cortical neurons of aged AD mice with respiration, ROS, synaptic, and Aβ readouts","pmids":["33951271"],"confidence":"High","gaps":["Did not establish whether Aβ clearance or presequence clearance is the dominant protective mechanism","Translatability of overexpression strategy to human disease unaddressed"]},{"year":2021,"claim":"Mapped the N-terminal domain as required for function, with a canine deletion causing respiratory chain deficiency, Aβ accumulation, and lethal epilepsy.","evidence":"Homozygosity mapping, genome sequencing, brain respiratory chain enzyme assays, and yeast complementation of the mutation","pmids":["33835239"],"confidence":"Medium","gaps":["Single lab; precise structural role of the lost N-terminal residues not defined","Mechanism linking the variant to respiratory chain deficiency unresolved"]},{"year":2023,"claim":"Connected presequence accumulation to a feedback loop that dissipates membrane potential and inhibits MPP, impairing Frataxin maturation, and identified PPARG activation as a route to upregulate PITRM1.","evidence":"MTS accumulation, membrane potential, MPP activity, and Frataxin maturation assays with pioglitazone treatment in patient vs. control fibroblasts","pmids":["37576821"],"confidence":"Medium","gaps":["Single lab in fibroblasts; not validated in neurons or in vivo","Direct biochemical mechanism of MPP feedback inhibition not resolved"]},{"year":null,"claim":"The structural basis of PITRM1 substrate selection and the precise mechanism coupling presequence accumulation to MPP feedback inhibition and downstream tau pathology remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure-function map of catalytic and substrate-length determinants","Causal ordering of Aβ, presequence, and tau pathology not established","Therapeutic upregulation strategies untested in vivo"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,3]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,4,5]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,5]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[2]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,4]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q5JRX3","full_name":"Presequence protease, mitochondrial","aliases":["Pitrilysin metalloproteinase 1","Metalloprotease 1","hMP1"],"length_aa":1037,"mass_kda":117.4,"function":"Metalloendopeptidase of the mitochondrial matrix that functions in peptide cleavage and degradation rather than in protein processing (PubMed:10360838, PubMed:16849325, PubMed:19196155, PubMed:24931469). Has an ATP-independent activity (PubMed:16849325). Specifically cleaves peptides in the range of 5 to 65 residues (PubMed:19196155). Shows a preference for cleavage after small polar residues and before basic residues, but without any positional preference (PubMed:10360838, PubMed:19196155, PubMed:24931469). Degrades the transit peptides of mitochondrial proteins after their cleavage (PubMed:19196155). Also degrades other unstructured peptides (PubMed:19196155). It is also able to degrade amyloid-beta protein 40, one of the peptides produced by APP processing, when it accumulates in mitochondrion (PubMed:16849325, PubMed:24931469, PubMed:26697887). It is a highly efficient protease, at least toward amyloid-beta protein 40 (PubMed:24931469, PubMed:29383861, PubMed:29764912). Cleaves that peptide at a specific position and is probably not processive, releasing digested peptides intermediates that can be further cleaved subsequently (PubMed:24931469). It is also able to degrade amyloid-beta protein 42 (PubMed:29764912)","subcellular_location":"Mitochondrion; Mitochondrion matrix","url":"https://www.uniprot.org/uniprotkb/Q5JRX3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PITRM1","classification":"Not Classified","n_dependent_lines":344,"n_total_lines":1208,"dependency_fraction":0.2847682119205298},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PITRM1","total_profiled":1310},"omim":[{"mim_id":"619405","title":"SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 30; SCAR30","url":"https://www.omim.org/entry/619405"},{"mim_id":"618211","title":"PITRILYSIN METALLOPEPTIDASE 1; PITRM1","url":"https://www.omim.org/entry/618211"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PITRM1"},"hgnc":{"alias_symbol":["MP1","KIAA1104","hMP1","PreP"],"prev_symbol":[]},"alphafold":{"accession":"Q5JRX3","domains":[{"cath_id":"3.30.830.10","chopping":"34-297","consensus_level":"high","plddt":98.0034,"start":34,"end":297},{"cath_id":"3.30.830.10","chopping":"317-507","consensus_level":"medium","plddt":95.7372,"start":317,"end":507},{"cath_id":"3.30.830.10","chopping":"854-1037","consensus_level":"medium","plddt":97.5223,"start":854,"end":1037}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q5JRX3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q5JRX3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q5JRX3-F1-predicted_aligned_error_v6.png","plddt_mean":94.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PITRM1","jax_strain_url":"https://www.jax.org/strain/search?query=PITRM1"},"sequence":{"accession":"Q5JRX3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q5JRX3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q5JRX3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q5JRX3"}},"corpus_meta":[{"pmid":"32632204","id":"PMC_32632204","title":"Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer's disease-like pathology in human cerebral organoids.","date":"2020","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/32632204","citation_count":107,"is_preprint":false},{"pmid":"1447789","id":"PMC_1447789","title":"Cloning and analysis of the entire Escherichia coli ams gene. ams is identical to hmp1 and encodes a 114 kDa protein that migrates as a 180 kDa protein.","date":"1992","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1447789","citation_count":99,"is_preprint":false},{"pmid":"8415644","id":"PMC_8415644","title":"RNase E activity is conferred by a single polypeptide: overexpression, purification, and properties of the ams/rne/hmp1 gene product.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8415644","citation_count":80,"is_preprint":false},{"pmid":"26697887","id":"PMC_26697887","title":"Defective PITRM1 mitochondrial peptidase is associated with Aβ amyloidotic neurodegeneration.","date":"2016","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26697887","citation_count":65,"is_preprint":false},{"pmid":"7600977","id":"PMC_7600977","title":"A 25.7 x 10(3) M(r) hydra metalloproteinase (HMP1), a member of the astacin family, localizes to the extracellular matrix of Hydra vulgaris in a head-specific manner and has a developmental function.","date":"1995","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/7600977","citation_count":50,"is_preprint":false},{"pmid":"29764912","id":"PMC_29764912","title":"Mitochondrial PITRM1 peptidase loss-of-function in childhood cerebellar atrophy.","date":"2018","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29764912","citation_count":31,"is_preprint":false},{"pmid":"34356897","id":"PMC_34356897","title":"Role of PITRM1 in Mitochondrial Dysfunction and Neurodegeneration.","date":"2021","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/34356897","citation_count":26,"is_preprint":false},{"pmid":"32857715","id":"PMC_32857715","title":"Expression of IDE and PITRM1 genes in ERN1 knockdown U87 glioma cells: effect of hypoxia and glucose deprivation.","date":"2020","source":"Endocrine regulations","url":"https://pubmed.ncbi.nlm.nih.gov/32857715","citation_count":24,"is_preprint":false},{"pmid":"33835239","id":"PMC_33835239","title":"In-frame deletion in canine PITRM1 is associated with a severe early-onset epilepsy, mitochondrial dysfunction and neurodegeneration.","date":"2021","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33835239","citation_count":13,"is_preprint":false},{"pmid":"19877269","id":"PMC_19877269","title":"The metalloendopeptidase gene Pitrm1 is regulated by hedgehog signaling in the developing mouse limb and is expressed in muscle progenitors.","date":"2009","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/19877269","citation_count":12,"is_preprint":false},{"pmid":"37576821","id":"PMC_37576821","title":"PPAR-gamma agonist pioglitazone recovers mitochondrial quality control in fibroblasts from PITRM1-deficient patients.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37576821","citation_count":8,"is_preprint":false},{"pmid":"33951271","id":"PMC_33951271","title":"Gain of PITRM1 peptidase in cortical neurons affords protection of mitochondrial and synaptic function in an advanced age mouse model of Alzheimer's disease.","date":"2021","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/33951271","citation_count":7,"is_preprint":false},{"pmid":"39236238","id":"PMC_39236238","title":"Single-molecule force spectroscopy reveals intra- and intermolecular interactions of Caenorhabditis elegans HMP-1 during mechanotransduction.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/39236238","citation_count":6,"is_preprint":false},{"pmid":"36867663","id":"PMC_36867663","title":"SRGP-1/srGAP and AFD-1/afadin stabilize HMP-1/⍺-catenin at rosettes to seal internalization sites following gastrulation in C. elegans.","date":"2023","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36867663","citation_count":6,"is_preprint":false},{"pmid":"36539037","id":"PMC_36539037","title":"The nematode α-catenin ortholog, HMP1, has an extended α-helix when bound to actin filaments.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36539037","citation_count":4,"is_preprint":false},{"pmid":"26919528","id":"PMC_26919528","title":"Purification, crystallization and initial crystallographic analysis of the α-catenin homologue HMP-1 from Caenorhabditis elegans.","date":"2016","source":"Acta crystallographica. Section F, Structural biology communications","url":"https://pubmed.ncbi.nlm.nih.gov/26919528","citation_count":3,"is_preprint":false},{"pmid":"35751131","id":"PMC_35751131","title":"PITRM1 interaction studies with amyloidogenic nonapeptide mutants of familial Alzheimer's disease.","date":"2022","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/35751131","citation_count":2,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.09.642261","title":"An extensive and unbiased genome-wide scan for parent-of-origin expressed genes in the pig clarifies the conservation landscape of genomic imprinting","date":"2025-03-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.09.642261","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12222,"output_tokens":2036,"usd":0.033603,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9114,"output_tokens":2581,"usd":0.055047,"stage2_stop_reason":"end_turn"},"total_usd":0.08865,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"PITRM1 is a mitochondrial matrix enzyme responsible for degrading mitochondrial targeting sequences (MTS) cleaved from imported precursor proteins and for digesting the mitochondrial fraction of amyloid-beta (Aβ). A homozygous missense mutation (p.Arg183Gln) reduces its proteolytic activity, resulting in Aβ accumulation in patient fibroblasts, skeletal muscle, and a yeast model. Heterozygous Pitrm1+/- mice develop progressive ataxia with brain Aβ-positive amyloid deposits, providing direct mechanistic evidence that PITRM1 loss impairs Aβ clearance leading to amyloidotic neurodegeneration.\",\n      \"method\": \"In vitro peptidase activity assay, patient fibroblast and skeletal muscle analysis, yeast complementation model, heterozygous mouse model with neuropathology\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods across in vitro, cellular, yeast, and mouse models; replicated across subsequent independent studies\",\n      \"pmids\": [\"26697887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A novel PITRM1 missense mutation (p.T931M) reduces PITRM1 protein levels by ~95% and specifically impairs cleavage of peptides ≥40 amino acids, demonstrating that the length of the substrate peptide is a determinant of PITRM1 enzymatic activity, with longer peptides being preferentially affected by this variant.\",\n      \"method\": \"Whole exome/genome sequencing, quantitative peptide cleavage activity assays in patient cells and yeast model\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct peptide cleavage activity assay plus yeast modeling, single lab\",\n      \"pmids\": [\"29764912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PITRM1 deficiency in human iPSC-derived cortical neurons strongly induces the mitochondrial unfolded protein response (UPRmt) and enhances mitochondrial clearance (mitophagy). PITRM1-knockout cerebral organoids spontaneously develop AD-like pathology including amyloid precursor protein and Aβ accumulation, tau pathology, protein aggregates, and neuronal cell death, establishing that impaired mitochondrial presequence processing triggers proteotoxic stress and UPRmt as an early protective response.\",\n      \"method\": \"PITRM1-knockout human iPSC-derived cortical neurons and cerebral organoids, single-cell RNA sequencing, immunohistochemistry for Aβ/tau/aggregates\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout in human iPSC-derived 3D organoid model with multiple orthogonal readouts (UPRmt, mitophagy, Aβ, tau, cell death, scRNA-seq)\",\n      \"pmids\": [\"32632204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Increasing neuronal PITRM1 expression/activity in aged AD transgenic mice (up to 19–24 months) re-established mitochondrial respiration, suppressed reactive oxygen species, improved synaptic function, and reduced synapse loss. Loss of PITRM1 proteolytic activity (catalytic mutant) abolished these rescue effects and resulted in Aβ accumulation, demonstrating that PITRM1 proteolytic activity is specifically required for mitochondrial Aβ clearance and protection of mitochondrial and synaptic function.\",\n      \"method\": \"Transgenic mouse model overexpressing PITRM1 or proteolytic-dead PITRM1 in cortical neurons; mitochondrial respiration assay, ROS measurement, synaptic function assessment, Aβ quantification\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain-of-function and catalytic mutant (loss-of-function) in vivo with multiple orthogonal functional readouts in aged AD mouse model\",\n      \"pmids\": [\"33951271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"An in-frame 6-bp deletion in canine PITRM1 (loss of two N-terminal residues) causes severe mitochondrial respiratory chain deficiency in brain tissue, Aβ accumulation, and lethal epilepsy. Yeast modeling of the mutation confirmed impaired growth and reduced respiration capacity, establishing that the N-terminal domain of PITRM1 is required for proper protein function and mitochondrial respiratory integrity.\",\n      \"method\": \"Homozygosity mapping, genome sequencing, mitochondrial respiratory chain enzyme activity assay in brain tissue, yeast complementation model\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct respiratory chain assay in affected tissue plus yeast functional model, single lab\",\n      \"pmids\": [\"33835239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PITRM1 dysfunction causes accumulation of mitochondrial targeting sequences (MTS), which dissipates mitochondrial membrane potential and triggers feedback inhibition of the mitochondrial processing peptidase (MPP), impairing maturation of Frataxin. Pharmacological activation of PPARG by pioglitazone upregulates both IDE and PITRM1 protein levels, restoring presequence processing, Frataxin maturation, and mitochondrial function in patient fibroblasts.\",\n      \"method\": \"MTS accumulation assay, mitochondrial membrane potential measurement, MPP activity assay, Frataxin maturation western blot, pharmacological treatment with pioglitazone in patient vs. control fibroblasts\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal biochemical assays in patient fibroblasts, single lab\",\n      \"pmids\": [\"37576821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Mouse Pitrm1 expression is upregulated in response to loss of the Gli3 transcription factor and is expressed in Pax3-positive myoblast progenitors, dermomyotome, and developing muscles. Pitrm1 expression is regulated downstream of hedgehog signaling in the developing limb, placing it in the Shh/Gli3 pathway during embryonic development.\",\n      \"method\": \"In situ hybridization in Gli3, Shh null, and Ptch1 conditional mutant mouse limbs; co-expression with Pax3 lineage marker\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — expression/localization data in mutant mice without functional rescue or direct epistasis experiment\",\n      \"pmids\": [\"19877269\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PITRM1 is a mitochondrial matrix zinc metallopeptidase that degrades mitochondrial targeting sequences (MTS) released after precursor protein import and clears the mitochondrial fraction of amyloid-beta (Aβ); loss of its proteolytic activity causes MTS accumulation, mitochondrial membrane potential dissipation, feedback inhibition of MPP (impairing Frataxin maturation), induction of the mitochondrial unfolded protein response, and progressive Aβ accumulation leading to neurodegeneration, while gain of PITRM1 activity restores mitochondrial respiration and synaptic function in AD mouse models.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PITRM1 is a mitochondrial matrix zinc metallopeptidase central to mitochondrial protein quality control, degrading the mitochondrial targeting sequences (presequences) released from imported precursor proteins and clearing the mitochondrial pool of amyloid-beta (Aβ) [#0]. Its catalytic activity is required for these functions: a catalytically dead enzyme fails to clear Aβ and abolishes rescue of mitochondrial respiration and synaptic integrity in aged AD mouse models, whereas restoring PITRM1 activity re-establishes respiration, suppresses reactive oxygen species, and reduces synapse loss [#3]. Substrate handling is length-dependent, with longer peptides (≥40 residues) preferentially affected by hypomorphic variants [#1]. When PITRM1 is impaired, undegraded presequences accumulate and dissipate the mitochondrial membrane potential, which feeds back to inhibit the mitochondrial processing peptidase (MPP) and blocks Frataxin maturation [#5]. Loss of activity also triggers the mitochondrial unfolded protein response and enhanced mitophagy as protective responses, while in human iPSC-derived cortical neurons and cerebral organoids PITRM1 deficiency drives Aβ and tau accumulation, protein aggregation, and neuronal death [#2]. Human and canine loss-of-function mutations cause progressive neurodegeneration, ataxia, amyloid deposition, respiratory chain deficiency, and lethal epilepsy, establishing PITRM1 loss as a direct cause of amyloidotic neurodegenerative disease [#0, #4]. Pharmacological upregulation of PITRM1 by PPARG activation (pioglitazone) restores presequence processing and Frataxin maturation in patient fibroblasts [#5].\",\n  \"teleology\": [\n    {\n      \"year\": 2016,\n      \"claim\": \"Established PITRM1 as a mitochondrial matrix peptidase whose loss impairs degradation of presequences and Aβ, causally linking it to amyloidotic neurodegeneration.\",\n      \"evidence\": \"In vitro peptidase assays, patient fibroblast/muscle analysis, yeast complementation, and a heterozygous mouse model with brain amyloid neuropathology\",\n      \"pmids\": [\"26697887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve substrate length preference or the structural basis of catalysis\", \"Mechanism connecting presequence accumulation to downstream mitochondrial dysfunction not yet defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed that substrate peptide length is a determinant of PITRM1 activity, with a hypomorphic variant selectively impairing cleavage of peptides ≥40 residues.\",\n      \"evidence\": \"Exome/genome sequencing plus quantitative peptide cleavage assays in patient cells and yeast\",\n      \"pmids\": [\"29764912\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; structural explanation for length selectivity not provided\", \"Relationship between reduced protein level and intrinsic catalytic defect not separated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined the cellular consequences of PITRM1 loss in human neurons—UPRmt and mitophagy induction as early protective responses, with organoids developing full AD-like pathology.\",\n      \"evidence\": \"PITRM1-knockout iPSC-derived cortical neurons and cerebral organoids with scRNA-seq and Aβ/tau/aggregate immunohistochemistry\",\n      \"pmids\": [\"32632204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal chain from presequence/Aβ accumulation to tau pathology not mechanistically dissected\", \"Whether UPRmt induction is sufficient to delay degeneration untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated that PITRM1 proteolytic activity specifically protects mitochondrial respiration and synaptic function, since gain of activity rescues AD mice and a catalytic mutant abolishes rescue.\",\n      \"evidence\": \"Transgenic overexpression of wild-type vs. proteolytic-dead PITRM1 in cortical neurons of aged AD mice with respiration, ROS, synaptic, and Aβ readouts\",\n      \"pmids\": [\"33951271\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether Aβ clearance or presequence clearance is the dominant protective mechanism\", \"Translatability of overexpression strategy to human disease unaddressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mapped the N-terminal domain as required for function, with a canine deletion causing respiratory chain deficiency, Aβ accumulation, and lethal epilepsy.\",\n      \"evidence\": \"Homozygosity mapping, genome sequencing, brain respiratory chain enzyme assays, and yeast complementation of the mutation\",\n      \"pmids\": [\"33835239\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; precise structural role of the lost N-terminal residues not defined\", \"Mechanism linking the variant to respiratory chain deficiency unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected presequence accumulation to a feedback loop that dissipates membrane potential and inhibits MPP, impairing Frataxin maturation, and identified PPARG activation as a route to upregulate PITRM1.\",\n      \"evidence\": \"MTS accumulation, membrane potential, MPP activity, and Frataxin maturation assays with pioglitazone treatment in patient vs. control fibroblasts\",\n      \"pmids\": [\"37576821\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab in fibroblasts; not validated in neurons or in vivo\", \"Direct biochemical mechanism of MPP feedback inhibition not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of PITRM1 substrate selection and the precise mechanism coupling presequence accumulation to MPP feedback inhibition and downstream tau pathology remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure-function map of catalytic and substrate-length determinants\", \"Causal ordering of Aβ, presequence, and tau pathology not established\", \"Therapeutic upregulation strategies untested in vivo\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 4, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":7,"faith_pct":85.71428571428571}}